Skip to main content

Table 2 Treatment after recurrence

From: Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma

Case number PFS duration (months) First site of recurrence Number of treatments after recurrence
Surgery C-ion RT RFA TACE TAI Molecular targeted therapy
1 1.7 Intrahepatic recurrence None None None 2 None None
2a 50.9 Distant metastases (lung) None 1 None None None 1 (Lenvatinib)
3 9.5 Intrahepatic recurrence None None None 1 None 1 (Sorafenib)
4 24.7 No recurrence None None None None None None
5 9.3 Intrahepatic recurrence 1 None 1 3 None 2 (Sorafenib and Lenvatinib)
6b 12.2 Distant metastases (lung) 1 1 1 None 1 None
7 3.6 Intrahepatic recurrence None None 1 None None 1 (Sorafenib)
8 8.6 Intrahepatic recurrence None None 1 None None 1 (Sorafenib)
9 1.2 Intrahepatic recurrence None None None 1 None 1 (Lenvatinib)
10 2.1 Intrahepatic recurrence None None None 1c None None
11 1.8 Local recurrence None None None None None None
  1. aPatient in Case 2 had local recurrence after distant metastases to the lung and received C-ion RT for local recurrence as a re-irradiation
  2. bPatient in Case 6 had intrahepatic recurrence outside the target region after distant metastases to the lung, who received surgery for the lung metastases and C-ion RT for the intrahepatic recurrence
  3. cPatient in Case 10 received transarterial embolization
  4. Abbreviations: C-ion RT carbon ion radiotherapy, PFS progression-free survival, RFA percutaneous radiofrequency ablation, TACE transarterial chemoembolization, TAI transcatheter arterial infusion chemotherapy